DrInes Cebola

Most of the genetic factors that associate with common human diseases reside in noncoding sequences. I aim to understand how specific noncoding sequences can affect the regulation of metabolic functions and contribute to human metabolic disease. My team applies both computational and experimental approaches to better elucidate molecular processes involved in the development of metabolic dysfunction, having a particular interest in non-alcoholic fatty liver disease and other pathologies affecting the liver. In the future, we will also explore the intricate relationship between liver cell dysfunction and the development of type 2 diabetes and cardiovascular disease.


My medium-term goals are:

- to characterise the multi-omic landscape of the human liver across chronic liver disease stages,

- to study the contribution of individual liver cell types to liver disease genetic risk profiles,

- to develop and apply CRISPR/Cas9 functional screens to identify noncoding sequences that directly impact liver cell metabolic outputs.